Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GSK3987 is an LXR ligand. GSK3987 recruits the steroid receptor coactivator-1 to human LXRalpha and LXRbeta with EC50s of 40 nM.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 97.00 | |
5 mg | In stock | $ 255.00 | |
10 mg | In stock | $ 413.00 | |
25 mg | In stock | $ 692.00 | |
50 mg | In stock | $ 985.00 | |
100 mg | In stock | $ 1,330.00 | |
500 mg | In stock | $ 2,660.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 277.00 |
Description | GSK3987 is an LXR ligand. GSK3987 recruits the steroid receptor coactivator-1 to human LXRalpha and LXRbeta with EC50s of 40 nM. |
Targets&IC50 | LXRβ:40 nM(EC50), LXRα:40 nM(EC50) |
In vitro | In primary human macrophages, GSK3987 (30, 100, 300, 1000 nM) increased the expression of ABCA1 and induces cellular cholesterol efflux to apoA1 particles in a dose-dependent manner. In human hepatoma (HepG2) cells, GSK3987 (6-1500 nM) increases the expression of SREBP-1c and induces triglyceride accumulation in a dose-dependent manner[1]. GSK3987 showed activity with EC50s of 0.08 μM, 50 nM, 40 nM for ABCA1, LXRα-SRC1, LXRβ-SRC1, respectively[1]. |
Molecular Weight | 384.43 |
Formula | C24H20N2O3 |
CAS No. | 264206-85-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/ml (130.06 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GSK3987 264206-85-1 Metabolism Liver X Receptor macrophages cellular cholesterol inhibit ABCA1 HepG2 cells Inhibitor SREBP-1c GSK-3987 LXR Liver X receptor triglyceride accumulation GSK 3987 inhibitor